CNS Pharmaceuticals, Inc. 8-K

What Happened CNS Pharmaceuticals, Inc. announced the hiring of Dr. Lynne Kelley as its new Chief Medical Officer, under an employment agreement dated February 26, 2026, with an effective start date of March 2, 2026. The company also entered a separation and severance agreement with former Chief Medical Officer Dr. Sandra Silberman on February 27, 2026, memorializing her exit from the company.

Key Details

• Dr. Lynne Kelley’s initial annual base salary is $450,000 and she is eligible for an annual bonus with a target equal to 40% of base salary.
• Initial equity award to Dr. Kelley: 9,500 restricted stock units (RSUs) vesting 25% at six months, 25% at 12 months, and the remaining 50% in twelve quarterly installments, subject to continued employment.
• Termination protections for Dr. Kelley: if terminated without cause or she leaves for good reason, she is eligible for six months of base salary severance (paid over six months), a pro-rated target bonus for the relevant period, and accelerated vesting of unvested equity (subject to release and covenants).
• Dr. Silberman’s separation provides severance equal to three months of her current annualized base salary, payable in three monthly installments, subject to execution and non-revocation of the separation agreement.

Why It Matters This is a material executive change affecting the company’s clinical and medical leadership. Dr. Kelley brings extensive clinical development and CMO experience at biotech and pharmaceutical companies, which could impact CNSP’s clinical programs and regulatory strategy. The financial commitments are limited to customary executive pay, a modest one-time equity grant (9,500 RSUs), and short-term severance obligations for both the incoming and outgoing CMO. Investors should note the change in leadership but the filing does not report any related-party transactions or unusual ongoing compensation exposure.